ライフサイエンスコーパス: analgesic agent

1 h endogenous release and its use as a potent analgesic agent.

2 ohasubanonine was found to be an ineffective analgesic agent.

3 lar blocking agent (NMBA) without a sedative/analgesic agent.

4 erstanding of which may extend its use as an analgesic agent.

5 ostoperative pain relief compared with other analgesic agents.

6 subject of great interest as potential novel analgesic agents.

7 rties, these compounds could be developed as analgesic agents.

8 tive cholinergic agonists will provide novel analgesic agents.

9 ll as blockade of the unwanted GI actions of analgesic agents.

10 be used as a template for the development of analgesic agents.

11 d antifungal agents), antiemetic agents, and analgesic agents.

12 hway may present a target for a new class of analgesic agents.

13 s, depth of sedation, and concomitant use of analgesic agents.

14 ffer strategies for the development of novel analgesic agents.

15 nzofurans (DHDMBFs) are antiinflammatory and analgesic agents.

16 ound to be nonsteroidal antiinflammatory and analgesic agents.

17 potential nonsteroidal antiinflammatory and analgesic agents.

18 specific clinical applications for adjuvant analgesic agents.

19 her compounds are disclosed as novel, potent analgesic agents acting through neuronal nicotinic acety

20 It allows for gradual weaning from sedative/analgesic agents after prolonged sedation while eliminat

21 adrenergic agonists, a new class of sedative/analgesic agents and their possible application for cons

22 We also examine the development of new analgesic agents and treatment modalities and regimens f

23 Opiates and acetaminophen are preferred analgesic agents, and gabapentin is a contextual third c

24 a major health concern even though numerous analgesic agents are available.

25 core and a decreased or stable use of rescue analgesic agents, as recorded in a daily electronic diar

26 selective CB2 agonism may afford a superior analgesic agent devoid of the centrally mediated CB1 eff

27 otent muscle relaxant, antiinflammatory, and analgesic agent (E)-2-(4,6-difluoro-1-indanylidene)aceta

28 mer and to the prototypical potent nicotinic analgesic agent (+/-)-epibatidine, 5 shows diminished ac

29 The use of gabapentin as an effective analgesic agent for neuropathic pain has expanded consid

30 Development of analgesic agents for the treatment of severe pain requir

31 evidence that AK inhibitors may be useful as analgesic agents in a broad spectrum of pain states.

32 and NGF-neutralizing molecules are effective analgesic agents in many models of persistent pain.

33 and NGFneutralizing molecules are effective analgesic agents in many models of persistent pain.

34 review the evidence for the use of nonopioid analgesic agents in patients with cancer and describe th

35 cy, and withdrawal after the use of sedative/analgesic agents in the PICU population.

36 s after prolonged administration of sedative/analgesic agents include slowly tapering the intravenous

37 Clinical evaluation of 5f as a novel analgesic agent is currently underway.

38 Morphine, a highly potent analgesic agent, is frequently prescribed for moderate t

39 Epidural analgesia, regardless of analgesic agent, location of catheter placement, and typ

40 sed the responsiveness of the measure to the analgesic agent remifentanil.

41 The activation pattern with analgesic agents seems to be specific to the class of dr

42 A 31-question analgesic agent survey was constructed, validated, and e

43 Because relief of pain is rewarding, analgesic agents that are not rewarding in the absence o

44 patient develops dental pain, we review the analgesic agents that are safe to take with warfarin and

45 therapeutics, including (i) fungistatic and analgesic agents that together generate fungicidal activ

46 elines allow physicians to give sedative and analgesic agents to dying patients if they intend to rel

47 Regular use of acetaminophen (an analgesic agent with little or no anti-inflammatory acti

48 ation of delirium and the use of sedative or analgesic agents with the outcomes were assessed with th

49 a-opioid agonists might represent more ideal analgesic agents, with fewer side effects.

50 Compound 2 is a potent antiinflammatory and analgesic agent without centrally acting muscle relaxant